摘要
新型生物学标志物-可溶性人基质裂解素-2(sST2)可以准确反映和预测与心力衰竭相关的心肌纤维化和心室重塑。众多研究已表明sST2是伴左心室射血分数降低的心力衰竭(HFrEF)患者病情进展、预后及死亡的独立预测因子。故考虑将sST2作为HFrEF患者心衰危险分层、进展情况、预后评估及进一步治疗调整的重要血清生物标志物指标。众多文献证实,在β受体阻滞剂逆转心力衰竭患者心室重塑的过程中,IL-33/sST2信号通路起到了巨大的作用,推测血清sST2的浓度可能受到β受体阻滞剂及其使用剂量的影响。
Soluble suppression of tumorigenicity 2(sST2)is a novel biomarker related to myocardial remodeling and myocardial fibrosis.sST2 has been proved to be an independent predictor of prognosis and death in patients with reduced ejection fraction heart failure(HFrEF).Therefore,it is considered to measure sST2 in the serum of HFrEF patients as an important indicator of risk stratification of heart failure,evaluation of prognosis and guidance of treatment.Studies have shown thatβreceptor blockers can reverse myocardial remodeling by regulating IL-33/sST2 signal transduction pathways.Therefore,the dose ofβreceptor blockers may affect the concentration of sST2.
作者
但素平(综述)
刘伟(审校)
DAN Su-ping;LIU Wei(Department of Cardiology,Chongqing Red Cross Hospital(People's Hospital of Jiangbei District),Chongqing 400000,China;Department of Traditional Chinese Medicine Hospital of Jiangjin District,Chongqing 402206,China)
出处
《微循环学杂志》
2022年第3期83-87,共5页
Chinese Journal of Microcirculation
关键词
可溶性ST2
Β受体阻滞剂
射血分数降低心力衰竭
Soluble suppression of tumorigenicity 2
βreceptor blockers
Reduced ejection fraction heart failure
